Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NuCana PLC NCNA

Healthcare Biotechnology
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC... see more

Recent & Breaking News (NDAQ:NCNA)

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

GlobeNewswire October 16, 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

GlobeNewswire October 13, 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

GlobeNewswire September 18, 2023

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 16, 2023

NuCana to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 17, 2023

NuCana Announces Receipt of Nasdaq Notice

GlobeNewswire May 12, 2023

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

GlobeNewswire April 14, 2023

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

GlobeNewswire April 4, 2023

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's '190 Patent is Not Valid

GlobeNewswire March 24, 2023

NuCana to Participate in Two Upcoming Investor Conferences

GlobeNewswire February 28, 2023

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire January 23, 2023

NuCana Announces Receipt of NASDAQ Notice

GlobeNewswire January 6, 2023

NuCana to Host Investor Meetings During the J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2023

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 16, 2022

NuCana to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 8, 2022

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

GlobeNewswire October 26, 2022

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

GlobeNewswire September 12, 2022

NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

GlobeNewswire September 12, 2022

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

GlobeNewswire September 6, 2022